Corrixr is developing a targeted genetic medicine designed to disable NRF2 in lung, head & neck, and esophageal squamous cell cancers.
Joined October 2023
- Tweets 66
- Following 25
- Followers 20
- Likes 30
21 Photos and videos
Corrixr Therapeutics retweeted
Congratulations new @CorriXR Therapeutics CEO Hilary Malone The #Delaware-based biotechnology company is working to bring transformative treatments to thousands of patients suffering from head & neck, lung and esophageal squamous cell cancers. delawarebusinesstimes.com/ne…
1
1
25
We’re thrilled to announce the appointment of Hilary M. Malone, PhD as Chief Executive Officer of Corrixr. She brings 25 years of drug development and executive leadership experience across clinical strategy and company building. Read the full announcement: businesswire.com/news/home/2…
#Biotech #Oncology #GeneticMedicine #Leadership
6
We are thrilled that Corrixr was featured by @DeBusinessTimes among the bioscience companies shaping what’s next in medicine.
Corrixr is developing breakthrough therapies for some of the deadliest and most difficult-to-treat squamous cell cancers by targeting the underlying biology tumors depend on to survive. We’re proud to advance this work from Delaware in a thriving life sciences community.
#oncology #geneediting #Corrixr #DelaProud
Delaware is home to several rising biotech companies, each looking to change the world through their therapeutics or technologies. Here's six companies that are rethinking medicine. #netde #InsiderOnly #biotech #Delaware
delawarebusinesstimes.com/in…
12
May 28
We are proud to be featured in @PrecMedOnline in a piece on the next frontier of #lungcancer treatment: inhaled gene therapies that fight tumors directly in the lungs. CorriXR's potential therapy targets #NRF2 - the biological switch that makes squamous cell lung tumors resistant to treatment. Knock it out, and standard-of-care works the way it should.
precisionmedicineonline.com/…
#GeneEditing #LUSC #Corrixr
8
This week, our CSO Eric B. Kmiec chairs Day 1 and presents on Day 2 at the 26th @BioPharmaNEXUS Drug Discovery in Philadelphia. His presentation focuses on a question with real consequences for patients: what initiates a squamous cell tumor is not what sustains it and targeting the right mechanism changes everything.
Join us to connect with industry pioneers and explore the future of drug discovery innovation.
👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗡𝗼𝘄: nexus-conference.com/ddneast…
#DrugDiscovery #GeneticMedicine #Oncology #NRF2 #Corrixr
5
Mar 17
CorriXR will be attending BIO-Europe Spring in Lisbon on March 23-25. Schedule a partnering meeting with Jan Case and Natalia Rivera-Torres to learn how our gene ablation approach for squamous cell carcinomas overcomes barriers to effective cancer treatment.
#BioEuropeSpring #BIOEurope #oncology
24
Jan 23
Our preclinical study just published in Molecular Therapy Oncology shows that #CRISPR-Cas9-mediated NRF2 disruption restores chemosensitivity in head and neck and esophageal squamous cell carcinoma models - extending our previous findings in lung cancer. These results support our plan to file an IND for #HNSCC - the first clinical application of our platform. #oncology #geneediting businesswire.com/news/home/2…
1
24
Corrixr Therapeutics retweeted
Congrats @CorriXR 🥳👏 The #Delaware life science startup inked a deal to develop a pioneering inhalable therapy to treat lung cancer. delawarebusinesstimes.com/ne…
2
2
113
2 Dec 2025
Combining CorriXR’s groundbreaking #CRISPR platform with @inhatarget pulmonary #LNP drug delivery and @MRXdevices #inhalation device technology has the potential to reshape the landscape of #lungcancer treatment. #oncology #geneediting businesswire.com/news/home/2…
1
41
17 Nov 2025
CorriXR is using #geneediting to make tumor cells more responsive to chemotherapy and slow tumor growth. Our collaborators @GeneEditingDE just published a study in @MolTherapy #Oncology during 🫁National Lung Cancer Awareness Month that sets a strong foundation for moving towards clinical trials for treatment in #lungcancer – and beyond to other tumor types. #CRISPR
businesswire.com/news/home/2…
14
30 Oct 2025
Congratulations to @RobertFerrisMD, a member of the CorriXR Clinical Advisory Board, on his election to the National Academy of Medicine!
20 Oct 2025
Huge congratulations to @RobertFerrisMD, PhD, UNC Lineberger executive director and Samantha Meltzer‑Brody, MD, MPH, executive dean of @UNC_SOM, on their election to the National Academy of Medicine (@theNAMedicine) - one of the highest honors in health and medicine. 🏆
Ferris and Meltzer-Brody are the only physicians in North Carolina elected to the Academy this year. Election to the Academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
We’re incredibly proud to have such visionary leaders working to advance patient care, research and innovation not just here in North Carolina, but around the world. news.unchealthcare.org/2025/…
1
35
Corrixr Therapeutics retweeted
16 Oct 2025
With a new COO and several consultants that were formerly as Spark Therapeutics, CorriXR plans on "rewriting the rules of cancer treatment." bizjournals.com/philadelphia…
1
1
335
Corrixr Therapeutics retweeted
9 Oct 2025
It’s a whirlwind week! From @CorriXR board meeting to moderating @ChicagoFed Payments Conference to interviewing @blackstone CEO at @federalreserve community bank conference, woah! BTW, CorriXR’s CEO, Dr. Kmiec, has the most incredible swag in his office - so many patents!
1
1
4
802
Corrixr Therapeutics retweeted
20 Aug 2025
Investing in Delaware’s innovators means investing in a healthier future. Newark-based CorriXR Therapeutics just received a $1M state grant to advance groundbreaking cancer gene-editing therapies—supporting local jobs, cutting-edge science, and life-saving treatments. Learn more: newarkpostonline.com/news/ne…
3
1
9
591
4 Aug 2025
Exciting news! CorriXR has been selected to present our next generation treatment for solid tumors at the @LifeSciencesPA conference on Sept 25/26. #oncology #geneediting #CRISPR
33
18 Jun 2025
Attending #BIO2025? Don't miss CorriXR's presentation on our next generation treatment for solid tumors on June 19 at 10:30 AM in Room 153B. #oncology #geneediting #CRISPR
1
28